



**Brilliant Violet 421™ anti-human TCR Vα24-Jα18 (iNKT cell)****Catalog # / Size:** 2314575 / 25 tests**Clone:** 6B11**Isotype:** Mouse IgG1, κ**Reactivity:** Human**Preparation:** The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 421™ and unconjugated antibody.**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).**Concentration:** Lot-specific

Human peripheral blood lymphocytes were stained with CD3 FITC and TCR Vα24-Jα18 (clone 6B11) Brilliant Violet 421™ (top) or mouse IgG1, κ Brilliant Violet 421™ isotype control (bottom).

**Applications:****Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.



Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

**Application Notes:** The 6B11 antibody recognizes the invariant CDR3 region of TCR Vα24-JαQ.

**Application References:** 1. Rout N, *et al.* 2010. *PLoS One* 5:e9787. (FC)

**Description:** Encoded by the TCR Vα24-Jα18 germline configuration, Vα24-JαQ is expressed on a subset of NKT cells, namely invariant NKT (iNKT). Vα24-JαQ TCR interacts with the glycolipid loaded MHC class 1b molecule CD1d, inducing activation and subsequent cytokine production. iNKT cells have been implicated in immune regulation, tumor surveillance, and host response to pathogens. While iNKT cells occur at low frequency in the blood, assorted chemokines contribute to their

tissue homing potential.

- Antigen**  
**References:**
1. Thomas SY, *et al.* 2003. *J. Immunol.* 171:2571.
  2. Exley MA, *et al.* 2008. *Eur. J. Immunol.* 38:1756.
  3. Montoya CJ, *et al.* 2007. *Immunology.* 122:1.
  4. Gansuud B, *et al.* 2003.